ReviewMedical principles and practice : international journal of the Kuwait University, Health Science Centre2017
Personalized Management of Cardiovascular Disorders.
Review in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial.Signal transduction and targeted therapy · 2021Trial
- Cardiovascular Aging: From Molecular Mechanisms to Targeted Therapies.Molecular diagnosis & therapy · 2025Review
- Artificial intelligence in interventional cardiology: a review of its role in diagnosis, decision-making, and procedural precision.Annals of medicine and surgery (2012) · 2025Review
- Revolutionizing Utility of Big Data Analytics in Personalized Cardiovascular Healthcare.Bioengineering (Basel, Switzerland) · 2025Review
- Environmental Factors and Cardiovascular Susceptibility: Toward Personalized Prevention Mediated by the Role of Artificial Intelligence-A Narrative Review.Health science reports · 2025Article
- The role of microbiome dysbiosis in cardiovascular disease: Mechanisms and therapeutic implications.Global cardiology science & practice · 2025Review
- Genetic Scale for Predicting the No-Reflow Phenomenon in Myocardial Infarction.Sovremennye tekhnologii v meditsine · 2025Article
- Treating Cardiovascular Disorders with Personalized Medicine.Cardiovascular & hematological disorders drug targets · 2025Review
- Echinacoside activates Nrf2/PPARγ signaling pathway to modulate mitochondrial fusion-fission balance to ameliorate ox-LDL-induced dysfunction of coronary artery endothelial cells.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Editorial Commentary on the Special Issue "Antioxidant Therapy for Cardiovascular Diseases"-Cutting-Edge Insights into Oxidative Stress and Antioxidant Therapy in Cardiovascular Health.Antioxidants (Basel, Switzerland) · 2024Article
- Exploring the Feasibility and Initial Impact of an mHealth-Based Disease Management Program for Chronic Ischemic Heart Disease: Formative Study.JMIR formative research · 2024Article
- Moderating Effect of Muscular Strength in the Association between Cardiovascular Events and Depressive Symptoms in Middle-Aged and Older Adults-A Cross Sectional Study.Geriatrics (Basel, Switzerland) · 2024Article
- The Role of Artificial Intelligence in Improving Patient Outcomes and Future of Healthcare Delivery in Cardiology: A Narrative Review of the Literature.Healthcare (Basel, Switzerland) · 2024Review
- Atherogenic index of plasma: a new indicator for assessing the short-term mortality of patients with acute decompensated heart failure.Frontiers in endocrinology · 2024Article
- Knockdown of lncRNA ENST00000609755.1 Confers Protection Against Early oxLDL-Induced Coronary Heart Disease.Frontiers in cardiovascular medicine · 2021Article
- Is Sex a Determinant of COVID-19 Infection? Truth or Myth?Current hypertension reports · 2020Review
- Perspectives in Individualizing Solutions for Dialysis Access.Advances in chronic kidney disease · 2020Review
- Article
- New steps for treating alcohol use disorder.Psychopharmacology · 2018Review
- Physical Activity and Cognitive Function among Older Adults with an Elevated Gamma Gap.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized management of cardiovascular disorders (CVD), also referred to as personalized or precision cardiology in accordance with general principles of personalized medicine, is selection of the best treatment for an individual patient. It involves the integration of various "omics" technologies such as genomics and proteomics as well as other new technologies such as nanobiotechnology. Molecular diagnostics and biomarkers are important for linking diagnosis with therapy and monitoring therapy. Because CVD involve perturbations of large complex biological networks, a systems biology approach to CVD risk stratification may be used for improving risk-estimating algorithms, and modeling of personalized benefit of treatment may be helpful for guiding the choice of intervention. Bioinformatics tools are helpful in analyzing and integrating large amounts of data from various sources. Personalized therapy is considered during drug development, including methods of targeted drug delivery and clinical trials. Individualized recommendations consider multiple factors - genetic as well as epigenetic - for patients' risk of heart disease. Examples of personalized treatment are those of chronic myocardial ischemia, heart failure, and hypertension. Similar approaches can be used for the management of atrial fibrillation and hypercholesterolemia, as well as the use of anticoagulants. Personalized management includes pharmacotherapy, surgery, lifestyle modifications, and combinations thereof. Further progress in understanding the pathomechanism of complex cardiovascular diseases and identification of causative factors at the individual patient level will provide opportunities for the development of personalized cardiology. Application of principles of personalized medicine will improve the care of the patients with CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.